Loading organizations...
Key people at Medifuture.
Medifuture provides a healthcare technology platform for direct personal health insights. Its product enables users to proactively monitor key indicators for heart, liver, kidney, and thyroid health without a doctor’s referral. The platform also guides sleep, energy, and weight management via hormone, blood sugar, metabolic analysis, supporting athletic performance optimization through biomarker tracking.
The company emerged from the insight that individuals seek more accessible, proactive health engagement. Its formation was driven by belief that direct physiological monitoring empowers better personal well-being, shifting focus toward preventative health management. Founding details, including names and precise inception date, are not publicly disclosed.
Medifuture serves health-conscious individuals and athletes aiming for optimization and longevity. The platform appeals to those valuing comprehensive self-monitoring and data-informed wellness strategies. Its vision is to democratize personalized health intelligence, empowering users to make informed decisions for long-term health.
Medifuture has 1 tracked investment across 1 company. The latest tracked deal is $25.3M Series B in Alivexis in May 2020.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| May 13, 2020 | Alivexis | $25.3M Series B | — | DAI Ichi Life, Essential Pharma, Miwa Toyoda, Kotaro Yamagishi, Mizuho Capital, Mobile Internet Capital, Koki Hirota, SMBC Venture Capital, UTokyo Innovation Platform |
Key people at Medifuture.